Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors

CAMBRIDGE, Mass., Feb. 16, 2018 -- (Healthcare Sales & Marketing Network) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Jessica Hopfield, Ph.D., to its Board of Directors, effective immediately... Biopharmaceuticals, Personnel Editas Medicine, genomic medicine, CRISPR
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news